No Data
Piper Sandler Sticks to Its Buy Rating for Cogent Biosciences (COGT)
H.C. Wainwright Maintains Cogent Biosciences(COGT.US) With Buy Rating, Cuts Target Price to $14
Buy Rating Maintained for Cogent Biosciences Amid Competitive Pressures and Promising Trial Results
Cogent Biosciences Price Target Lowered to $14 From $17 at H.C. Wainwright
Cogent Biosciences Announces 2025 Milestones, SUMMIT Results In NonAdvSM In July, PEAK Phase 3 In 2nd-Line GIST By Year-End, APEX In AdvSM in H2; Presenting at J.P. Morgan Healthcare Conference Tomorrow At 10:30 AM ET
Cogent Biosciences Announces Planned 2025 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics